Related Experiment Videos
Ribavirin response in measles pneumonia
S Gururangan1, R F Stevens, D J Morris
1Department of Paediatric Oncology, Royal Manchester Children's Hospital, U.K.
The Journal of Infection
|May 1, 1990
Summary
A child with Hodgkin
Area of Science:
- Pediatric Oncology
- Infectious Diseases
- Virology
Background:
- A 9-year-old boy with Hodgkin's disease underwent intensive chemotherapy.
- Measles infection occurred one month post-chemotherapy in an immunocompromised child.
Observation:
- The patient presented with an atypical measles rash and absence of Koplik's spots.
- This presentation suggested a high risk for developing fatal giant cell pneumonia.
- Initial nebulized and intravenous ribavirin therapy led to apparent recovery.
Findings:
- The child later developed confirmed measles giant cell pneumonia.
- A second course of ribavirin therapy was successful in treating the pneumonia.
- This case highlights the potential efficacy of ribavirin in severe measles cases.
Implications:
- Ribavirin may be a crucial therapeutic option for measles in immunocompromised pediatric patients.
- Early recognition of atypical measles presentations in immunocompromised children is vital.
- Further research into ribavirin's role in treating severe viral infections in oncology patients is warranted.